On September 4, WUXI BIO fell 3.12% in regular trading, trading at HK$49.02/share, with turnover of HK$1.456 billion. The stock had briefly rebounded nearly 3% in the prior session on buyback news before resuming its downward trajectory.

On the news front, the company's strong interim results disclosed on August 25 — reporting revenue of RMB 11.787 billion (up 18.4% YoY), gross profit of RMB 5.448 billion (up 28.1%), and adjusted net profit attributable to shareholders of RMB 3.306 billion (up 38.4%) — along with multiple investment banks raising target prices to HK$57–61, have been largely priced in during prior sessions. Meanwhile, the cumulative buyback of approximately 39.82 million shares totaling around HK$1.272 billion at a weighted average price of HK$31.93 per share has seen its supportive effect diminish, with profit-taking pressure continuing to build.

Sector-wide weakness further dragged sentiment, with peer GenScript Biotech plunging 11.63% and WuXi AppTec declining 0.57%, reflecting broad CXO sector pressure amid post-earnings rotation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)